Gómez Ballesteros, MiguelAndrés Guerrero, VanesaParra Luna, FranciscoMarinich, JorgeHeras Polo, Beatriz De LasMolina Martínez, Irene TeresaVázquez Lasa, BlancaSan Román Del Barrio, JulioHerrero Vanrell, María Del Rocío2023-06-172023-06-172019-07-19Gómez Ballesteros, M., Andrés Guerrero, V., Parra Luna, F. et al. «Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers». Polymers, vol. 11, n.o 7, julio de 2019, p. 1213. DOI.org (Crossref), https://doi.org/10.3390/polym11071213.Gómez Ballesteros, M., Andrés Guerrero, V., Parra Luna, F. et al. «Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers». Polymers, vol. 11, n.o 7, julio de 2019, p. 1213. DOI.org (Crossref), https://doi.org/10.3390/polym11071213.2073-436010.3390/polym11071213https://hdl.handle.net/20.500.14352/12759Topical application of drops containing ocular drugs is the preferred non-invasive route to treat diseases that a_ect the anterior segment of the eye. However, the formulation of eye drops is a major challenge for pharmacists since the access of drugs to ocular tissues is restricted by several barriers. Acetazolamide (ACZ) is a carbonic anhydrase inhibitor used orally for the treatment of ocular hypertension in glaucoma. However, large ACZ doses are needed which results in systemic side e_ects. Recently, we synthesized copolymers based on 2-hydroxyethyl methacrylate (HEMA) and a functionalized three-arm poloxamer star (Bayfit-MA). The new material (HEMA/Bayfit-MA) was engineered to be transformed into nanoparticles without the use of surfactants, which represents a significant step forward in developing new ophthalmic drug delivery platforms. Acetazolamide-loaded nanocarriers (ACZ-NPs) were prepared via dialysis (224 +/- 19 nm, ̶ 17.2 +/- 0.4 mV). The in vitro release rate of ACZ was constant over 24 h (cumulative delivery of ACZ: 83.3 +/- 8.4%). Following standard specifications, ACZ-NPs were not cytotoxic in vitro in cornea, conjunctiva, and macrophages. In normotensive rabbits, ACZ-NPs generated a significant intraocular pressure reduction compared to a conventional solution of ACZ (16.4% versus 9.6%) with the same dose of the hypotensive drug (20 μg). In comparison to previously reported studies, this formulation reduced intraocular pressure with a lower dose of ACZ. In summary, HEMA:Bayfit-MA nanoparticles may be a promising system for ocular topical treatments, showing an enhanced ocular bioavailability of ACZ after a single instillation on the ocular surface.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/polym11071213open access615.4617.7NanoparticlesGlaucomaAcetazolamideHEMA/Bayfit-MADrug deliveryOphthalmologyOftalmologíaTecnología farmaceútica3201.09 Oftalmología